Search
Brompheniramine
go.drugbank.com/drugs/DB00835ApprovedHistamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Synonyms: 3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, 3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamineMixtures: M-end Wc, M-end PEFluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigationalIt presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalGAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. … [A232955] In clinical trials, avalglucosidase alfa improved lung function in patients with Pompe disease.
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Fosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalepisodes in patients with hemophilia A. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Glycopyrronium
go.drugbank.com/drugs/DB00986ApprovedInvestigationalVet approved[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers. … [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA … The SVR12 was 83% (29/35) in treatment-naïve patients and 86% (19/22) in relapsing patients.
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … Rezafungin is an echinocandin antifungal drug.